Part 04 · The Company

Root to Life — a structure where evidence beats product opinion

The company holds the vision and the method, the project builds the evidence, and the product stays beside the patient. The same engine carries us to the next disease.

Why Three Layers

What each layer owns

LayerOwnsSpeaks toDefinition of success
Root to Life
company
Mission · entity · capital · IP · method · data governance · brand systemInvestors · partners · governmentBuild a structure that repeats across diseases
Kidney Bloom
project
Research · evidence · design principles · regulatory judgment · public contentClinicians · researchers · policyEvidence beats product opinion
My Beanie
product
User experience · records · communityPatients · caregiversIt gets opened every day

The expansion roadmap is My Beanie Kidney (now) → Heart / Sugar (2028) → Air (2029). Beanie, the record engine, the method, and the brand stay; only the disease changes. Project-layer names for later diseases (Heart Bloom · Sugar Bloom · Air Bloom) are working titles.

We don't call it a "medical platform" yet. Regulators in Korea judge intended use by how a product describes itself. A "wellness care platform" does the same work from a different seat. Rename once clinical evidence is in; do it in the wrong order and it is hard to undo.
The R&D Engine

Observation becomes evidence, evidence becomes a feature

The cycle is measured by The Self-Explanation Index: a cycle succeeds when users reach LV2.

01 Observe

Observe

Collect scenes that repeat in patient and caregiver interviews, communities, and clinics

02 Ground

Ground

Verify against clinical guidelines, literature, and statistics. No evidence, no next step

03 Design

Design

Translate into one cell of the 3×5 grid. No cell, no feature

04 Validate

Validate

Judge by gate conditions. Results and failures feed back into 01

Four research tracks

Track 1

Clinical Evidence

Interpretation ranges and wording for eGFR, creatinine, proteinuria / alignment with KDIGO and KSN guidelines / comorbidity interactions

Track 2

Behavioral Design

Rules for translating SDT's three needs into features / notification volume vs. churn / sharing that never becomes surveillance

Track 3

Policy & Regulation

Korean rare-disease copay relief, kidney disability registration, chronic-care reimbursement / MFDS wellness boundary / FDA General Wellness and CDS

Track 4

Data & Interoperability

FHIR R4 · US Core 3.1.1 / Apple Health Records requirements (SMART on FHIR, 8 required resources) / consent design

Five things Kidney Bloom produces

FormatWhat it isWhere it is used
Evidence NoteSourced claimSource for every product string and public content
Design PrincipleCell definitionDefines each cell of the 3×5 grid
Regulatory MemoRegulatory judgmentBasis for approving or shelving a feature
Metric SpecMetric definitionSelf-Explanation levels and gate conditions
Public ContentPublic materialInstagram carousels · case studies · kidneybloom.com
Rule: no claim reaches the product screen without an Evidence Note.
The Asset Stack

Four layers of accumulated assets, and how much carries over

Same engine, different disease. What ports as-is, and what must be rebuilt.

Method · ports as-is

Method

Index · grid · gates · four-step R&D

Brand · ports as-is

Brand

Tone · color · mascot · content formats

Data · structure only

Data

Consented longitudinal records · FHIR structure. Data itself is disease-specific

Relationships · rebuilt

Relationships

Advisors, pilot sites, and communities must be rebuilt per disease

Team & The Ask

Team and the ask

Trained in visual communication design; built the design system and template architecture for the investment banking division at Samsung Securities — compressing complex financial information into decision-ready form, which is structurally the same job My Beanie does. Research background in cognitive load theory and dual-process theory. The starting point is lived experience: managing a family member's kidney disease up close.

Eng
Web app (PWA) in operation. Native apps and privacy operations scale up with incorporation
Med
Advising nephrologist. Content review and clinical evidence design
Diet
Renal dietitian. Dietary content and the care-food line
BD
Pharma and hospital channel experience. For Lanes B and C

Before money, three things

01

Nephrology connections

Content review and first patient touchpoints. The most urgent asset.

02

Patient community access

Interviews and MVP testing with 20–30 pre-dialysis CKD patients.

03

Pharma and care-food introductions

To validate Lanes A and B within 12 months.

Then

Seed round

Size and timing decided on Phase 2 retention data. No valuation without metrics.

Partnerships & advising — hello@kidneybloom.com Open My Beanie
How We Work

Built with patients and clinicians

Before speed of shipping, we set the rule for what never goes on screen. Three principles apply to every screen and every line of copy.

01 · Patients first

It starts with patient and caregiver interviews

Which patient, which moment — decided first. Features are born only from those scenes, and real-user feedback sets the priorities for the next version.

02 · Clinical review

Copy reviewed by clinicians

The eGFR formula, the body-signal list, meal caution tags and dialysis log items are finalized under nephrologist advice and review. No claim goes on screen without an evidence note.

03 · On-device

Records stay on the patient's device

No server, no account to begin with. The app never diagnoses or alarms; judgment rests with the care team. Server and sign-in arrive together with a consent framework.

Current stage: MVP in real-user validation, pre-incorporation. Governance and IP structure are a draft, to be finalized on incorporation with legal counsel. All figures on this site are from 2025–2026 public sources; financial projections will be written only after real-user data exists.